Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/24824
Title: Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up.
Austin Authors: McClure, Tess ;Cui, Wanyuan;Asadi, Khashayar ;John, Thomas ;Testro, Adam G 
Affiliation: Gastroenterology and Hepatology
Anatomical Pathology
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Medicine (University of Melbourne)
Issue Date: Sep-2020
metadata.dc.date: 2020-09
Publication information: BMJ Open Gastroenterology 2020; 7(1): e000487
Abstract: Nivolumab is an immune checkpoint inhibitor used to treat multiple solid-organ malignancies. While many of its immune-related adverse events are well established, nivolumab-induced sclerosing cholangitis remains poorly characterised, with no defined diagnostic criteria. Moreover, data regarding long-term outcomes are particularly lacking. We present a biopsy-proven case of nivolumab-induced sclerosing cholangitis, which uniquely captures 18 months of follow-up post-treatment. Our case highlights key features of intrahepatic subtype sclerosing cholangitis and suggests durable response to corticosteroid therapy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/24824
DOI: 10.1136/bmjgast-2020-000487
ORCID: 0000-0003-2810-7443
PubMed URL: 32912846
ISSN: 2054-4774
Type: Journal Article
Subjects: autoimmune biliary disease
cancer immunobiology
cholestatic liver diseases
drug toxicity
liver function test
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Apr 17, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.